An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
Phase of Trial: Phase II/III
Latest Information Update: 10 Dec 2018
At a glance
- Drugs Seladelpar (Primary)
- Indications Cholangitis
- Focus Adverse reactions; Registrational
- Sponsors CymaBay Therapeutics
- 31 Aug 2018 Biomarkers information updated
- 08 Jan 2018 According to a CymaBay Therapeutics media release, Data from this trial will support the seladelpar registration program and to follow patients until registration of seladelpar.
- 08 Jan 2018 According to a CymaBay Therapeutics media release, first patient has been enrolled.